RxDoctor Payments Data

Karl Langberg, MD

Gastroenterology · Hamden, CTNPI 1285070730

Payments from drug & device makers

$16,781in general payments, 2019–2025

Across 167 payments — averaging $100.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$13K
  • AbbVie$1K
  • Ardelyx, Inc.$360
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$259
  • Takeda Pharmaceuticals U.S.A., Inc.$185
  • Bristol Myers Squibb$169
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$12,90077%
  • Grants$290%
  • Travel & lodging$390%
  • Food & beverage$3,81323%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,781 in reported general payments places this provider in the 80th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$74,920
Medicare patients
224
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$102,632
LinzessLinaclotide46$70,685
CreonLipase/Protease/Amylase17$56,641
OzempicSemaglutide28$25,337
VoqueznaVonoprazan Fumarate11$9,553
ClenpiqSod Picosulf/Mag Ox/Citric Ac27$4,700
Colestipol Hcl25$3,114
Omeprazole206$2,795
Ursodiol15$2,273
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,880
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates27$1,498
Ondansetron OdtOndansetron32$1,480
Pantoprazole Sodium83$1,133
Famotidine79$1,055
Sucralfate11$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,040$127,32663 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$259$104,51242 claims
Novo NordiskOzempic$120$25,33728 claims
Phathom Pharmaceuticals, Inc.Voquezna$13,489$9,55311 claims
Ferring Pharmaceuticals Inc.Clenpiq$28$4,70027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →